Last10K.com

Vanda Pharmaceuticals Inc. (VNDA) SEC Filing 10-Q Quarterly report for the period ending Sunday, September 30, 2018

Vanda Pharmaceuticals Inc.

CIK: 1347178 Ticker: VNDA

Exhibit 99.1

LOGO

Vanda Pharmaceuticals Reports Third Quarter 2018 Financial Results

 

   

Hetlioz® net product sales grew to $29.9 million in the third quarter of 2018, a 34% increase compared to the third quarter of 2017

   

Results from clinical studies of tradipitant in gastroparesis and HETLIOZ® in Smith-Magenis Syndrome are expected by the end of 2018

WASHINGTON – November 7, 2018 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq:

VNDA) today announced financial and operational results for the third quarter ended September 30, 2018.

Key Highlights:

 

   

Vanda reiterates 2018 net product sales guidance of $180 million to $200 million.

 

   

Total net product sales from HETLIOZ® and Fanapt® were $49.1 million during the third quarter of 2018, a 4% increase compared to $47.4 million in the second quarter of 2018 and a 19% increase compared to $41.3 million in the third quarter of 2017.

HETLIOZ® (tasimelteon)

 

   

HETLIOZ® net product sales were $29.9 million in the third quarter of 2018, a 7% increase compared to $28.0 million in the second quarter of 2018 and a 34% increase compared to $22.3 million in the third quarter of 2017.

Fanapt® (iloperidone)

 

   

Fanapt® net product sales were $19.2 million in the third quarter of 2018, a less than 1% decrease compared to $19.3 million in the second quarter of 2018 and a less than 1% increase compared to $19.1 million in the third quarter of 2017.

Research and Development

Tradipitant

 

   

Enrollment in the clinical study of tradipitant in gastroparesis is complete. Results are expected by the end of 2018.

   

The Phase III study (EPIONE) of tradipitant in atopic dermatitis is ongoing.

HETLIOZ® (tasimelteon)

 

   

Enrollment in the clinical study of HETLIOZ® in Smith-Magenis Syndrome is complete. Results are expected by the end of 2018.

   

Vanda submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for HETLIOZ® in jet lag disorder and expects a filing date by the end of 2018.

   

In September, a HETLIOZ® driving studying demonstrated no impairment of next day driving performance.

Fanapt® (iloperidone)

 

   

A pharmacokinetic study of the long acting injectable (Depot) formulation of Fanapt® enrolled its first patient during October 2018.

 

Page 1 of 7


The following information was filed by Vanda Pharmaceuticals Inc. (VNDA) on Wednesday, November 7, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Vanda Pharmaceuticals Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Vanda Pharmaceuticals Inc..

Continue

Assess how Vanda Pharmaceuticals Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Vanda Pharmaceuticals Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets (Unaudited)
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Changes In Stockholders' Equity (Unaudited)
Condensed Consolidated Statements Of Comprehensive Income (Loss) (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited)
Accounts Payable And Accrued Liabilities
Accounts Payable And Accrued Liabilities (Detail)
Accounts Payable And Accrued Liabilities (Tables)
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss) (Tables)
Accumulated Other Comprehensive Income (Loss) - Summary Of Accumulated Balances Related To Each Component Of Other Comprehensive Income (Loss) (Detail)
Accumulated Other Comprehensive Loss - Additional Information (Detail)
Business Organization And Presentation
Business Organization And Presentation (Detail)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - (Cftr Activators And Inhibitors) - Additional Information (Detail)
Commitments And Contingencies - (Fanapt) - Additional Information (Detail)
Commitments And Contingencies - (Hetlioz) - Additional Information (Detail)
Commitments And Contingencies - (Operating Leases) - Additional Information (Detail)
Commitments And Contingencies - (Tradipitant) - Additional Information (Detail)
Commitments And Contingencies - (Vqw-765) - Additional Information (Detail)
Commitments And Contingencies - Research And Development And Marketing Agreements (Details)
Commitments And Contingencies - Summary Of Minimum Annual Future Payments Under Operating Leases And Subleases For Office Space (Detail)
Earnings Per Share
Earnings Per Share (Detail)
Earnings Per Share (Tables)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Additional Information (Detail)
Fair Value Measurements - Assets Measured At Fair Value On Recurring Basis (Detail)
Income Taxes
Income Taxes (Detail)
Intangible Assets
Intangible Assets (Tables)
Intangible Assets - (Fanapt) - Additional Information (Detail)
Intangible Assets - (Hetlioz) - Additional Information (Detail)
Intangible Assets - Additional Information (Detail)
Intangible Assets - Summary Of Future Intangible Asset Amortization (Detail)
Intangible Assets - Summary Of Intangible Assets (Detail)
Inventory
Inventory (Detail)
Inventory (Tables)
Legal Matters
Marketable Securities
Marketable Securities (Tables)
Marketable Securities - For-Sale Marketable Securities (Detail)
Public Offering Of Common Stock
Public Offering Of Common Stock (Detail)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - (Rsu) - Additional Information (Detail)
Stock-Based Compensation - (Stock Option) - Additional Information (Detail)
Stock-Based Compensation - (Stock-Based Compensation) - Additional Information (Detail)
Stock-Based Compensation - Black-Scholes-Merton Option Pricing Model For Stock Options Granted (Detail)
Stock-Based Compensation - Summary Of Option Activity For 2006 Plan And The 2016 Plan (Detail)
Stock-Based Compensation - Summary Of Rsu Activity Plan (Detail)
Stock-Based Compensation - Total Stock-Based Compensation Expense (Detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Summary Of Significant Accounting Policies - Net Sales By Product (Detail)

Material Contracts, Statements, Certifications & more

Vanda Pharmaceuticals Inc. provided additional information to their SEC Filing as exhibits

Ticker: VNDA
CIK: 1347178
Form Type: 10-Q Quarterly Report
Accession Number: 0001347178-18-000010
Submitted to the SEC: Wed Nov 07 2018 5:08:34 PM EST
Accepted by the SEC: Wed Nov 07 2018
Period: Sunday, September 30, 2018
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/vnda/0001347178-18-000010.htm